peripheral neuropathy
To assess whether insulin-like growth factor-I (IGF-I), a neurotrophic agent that supports the survival of motoneurons and enhances regeneration of motor and sensory neurons, could prevent the peripheral neuropathy produced by vincristine, mice were treated with both vincristine (1.7 mg/kg, i.p., 2 x /week) and/or IGF-I (0.3 or 1 mg/kg, s.c. daily) for 10 weeks.
To assess whether <span class="gene" id="9452187-2-18-46">insulin-like growth factor-I</span> (<span class="gene" id="9452187-2-48-53">IGF-I</span>), a neurotrophic agent that supports the survival of motoneurons and enhances regeneration of motor and sensory neurons, could prevent the <span class="disease" id="9452187-2-193-214">peripheral neuropathy</span> produced by vincristine, mice were treated with both vincristine (1.7 mg/kg, i.p., 2 x /week) and/or <span class="gene" id="9452187-2-316-321">IGF-I</span> (0.3 or 1 mg/kg, s.c. daily) for 10 weeks.